A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
Status:
Completed
Trial end date:
2019-02-08
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the safety, plasma pharmacokinetics, and
maximum tolerated dose (MTD) of KD019 when administered to subjects with ADPKD.